Broad-spectrum antiviral activity of antisense oligonucleotides targeting GBF1 against SARS-CoV-2 and influenza viruses
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development (JP19fk0108113)
- Japan Agency for Medical Research and Development (JP223fa727001)
- Japan Agency for Medical Research and Development (JP223fa627002)
- Japan Agency for Medical Research and Development (JP22gm1610010)
- Japan Society for the Promotion of Science (JP22H02521)
- Japan Society for the Promotion of Science (JP24K09264)
- Research Institute for Microbial Diseases, Osaka University
- Takeda Science Foundation
This publication has 62 references indexed in Scilit:
- Host specific sphingomyelin is critical for replication of diverse RNA virusesCell Chemical Biology, 2024
- Emerging SARS-CoV-2 Resistance After Antiviral TreatmentJAMA Network Open, 2024
- Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease region of viral RNAAntiviral Research, 2024
- Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging virusesEuropean Journal of Medicinal Chemistry, 2023
- Generation of host-directed and virus-specific antivirals using targeted protein degradation promoted by small molecules and viral RNA mimicsCell Host & Microbe, 2023
- The host-targeting compound peruvoside has a broad-spectrum antiviral activity against positive-sense RNA virusesActa Pharmaceutica Sinica B, 2023
- Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide ExtensionMolecular Diagnosis & Therapy, 2022
- CSFV proliferation is associated with GBF1 and Rab2Journal of Biosciences, 2016
- Influenza Virus-Host Interactome Screen as a Platform for Antiviral Drug DevelopmentCell Host & Microbe, 2014
- Silencing disease genes in the laboratory and the clinicThe Journal of Pathology, 2011